Protagonist Therapeutics Stock (NASDAQ: PTGX)

Protagonist Therapeutics (NASDAQ:PTGX) Stock

PROTAGONIST THERAPEUTICS INC

Protagonist Therapeutics

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics Inc

Wells Fargo analyst Michael Berg upgrades Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) from Equal-Weight to Overweight and raises the price target from $32 to $40.

News

Upgrades

Price Target

Analyst Ratings

KVYO

Wells Fargo Upgrades Klaviyo to Overweight, Raises Price Target to $40

Wells Fargo analyst Michael Turrin downgrades ZoomInfo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTM#NASDAQ">GTM</a>) from Equal-Weight to Underweight and lowers the price target from $10 to $9.

Downgrades

Wells Fargo Downgrades ZoomInfo Technologies to Underweight, Lowers Price Target to $9

Rising Middle East tensions and President Donald Trump&#8217;s threats to Iran are flaring uncertainty in the global and U.S. markets. As a result, money is flowing from equities to safe-haven assets like gold.
Also, the crude oil price is soaring as rising conflict threatens OPEC crude supply.
<h2 class="wp-block-heading">Asia Markets Today</h2>
On Friday, Japan&#8217;s Nikkei 225 closed 0.92% lower at 37,821.50, led by losses in the Paper &amp; Pulp, Transport and Communication sectors.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Australia&#8217;s S&amp;P/ASX 200 was down 0.21% at 8,547.40, led by losses in the IT, Healthcare, and Telecoms Services sectors.
India&#8217;s Nifty 50 was down 0.71% at 24,712.40, and the Nifty 500 slid 0.65% to 22,895.65.
China&#8217;s Shanghai Composite was down 0.75% at 3,377.00, and Shanghai Shenzhen CSI 300 fell 0.72% to 3,864.18.
Hong Kong&#8217;s Hang Seng closed the session 0.59% lower at 23,892.56.
Related: <a target="_blank" href="https://www.benzinga.com/markets/commodities/25/06/45897276/oil-etfs-surge-over-6-as-trump-orders-middle-east-evacuation-amid-iran-tensions-warns-region-could-be-dangerous" rel="noreferrer noopener">Oil ETFs Surge Over 6% As Trump Orders Middle East Evacuation Amid Iran Tensions, Warns Region &#8216;Could Be Dangerous&#8217;</a>
<h2 class="wp-block-heading">Eurozone at 05:45 AM ET</h2>
The European STOXX 50 index was down 1.33%.
Germany&#8217;s DAX index declined 1.35%.
France&#8217;s CAC 40 fell 1.03%.
U.K.&#8217;s FTSE 100 index traded lower by 0.38%.
<h2 class="wp-block-heading">Commodities</h2>
At 05:45 AM ET, the crude Oil WTI was trading higher by 7.54% at $73.17/bbl, and Brent was up 74.38% at $74.31/bbl.
Oil prices surged over 7% on Friday, hitting multi-month highs after Israel struck Iran&#8217;s nuclear sites, prompting retaliation and fears of supply disruption.
Natural gas rose 1.03% to $3.529.
Gold traded higher by 1.24% to $3,444.40, Silver rose 0.54% to $36.493, and Copper fell 1.90% to $4.7440.
<h2 class="wp-block-heading">US Futures</h2>
At 05:45 AM ET, Dow Jones futures were down 1.14%, the S&amp;P 500 declined 1.19%, and the Nasdaq 100 was down 1.48%.
U.S. stock futures fell after Israel&#8217;s strike on Iran raised Middle East tensions, spiking oil prices and boosting energy and defense stocks.
On Thursday, June 12, U.S. markets ended higher as optimism over artificial intelligence lifted investor sentiment. The S&amp;P 500 gained ground, led by a surge in Oracle shares after the company raised its outlook on strong AI-related demand. Gains in tech and gold mining stocks offset worries over Middle East tensions and a decline in Boeing shares. Softer inflation and labor data boosted hopes for an interest rate cut.
According to the economic data, U.S. producer prices rose 0.1% in May, below the 0.2% forecast, after a revised 0.2% drop in April. Initial jobless claims held at 248,000, above expectations of 240,000.
Most S&amp;P 500 sectors advanced Thursday, led by utilities, tech, and health care, while communication services and consumer discretionary lagged.
<h2 class="wp-block-heading">Forex</h2>
At 05:45 AM ET, the U.S. Dollar Index gained 0.45% to 98.31, USD/JPY was up 0.41% to 144.05, and USD/AUD rose 0.82% to 1.5430.
The dollar rallied Friday as investors sought safe havens after Israel&#8217;s strikes on Iran triggered retaliation.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/market-summary/25/06/45918802/middle-east-tensions-rattle-markets-us-stock-futures-slide-oil-jumps-8-gold-surges-above-3400-after-israel-strikes-iran" target="_blank" rel="noreferrer noopener">Middle East Tensions Rattle Markets: US Stock Futures Slide, Oil Jumps 8%, Gold Surges Above $3,400 After Israel Strikes Iran</a></li>
</ul>
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Global Markets Slide As Iran-Israel Conflict Heats Up, Oil Soars

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) with a Buy and maintains $75 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target

Cloudflare, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) on Friday <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45921345/cloudflare-inc-announces-pricing-of-offering-of-1-75-billion-of-0-convertible-senior-notes-due-203" rel="noreferrer noopener">announced the pricing</a> of $1.75 billion convertible senior notes due 2030 in a private offering by institutional buyers.
The company also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $250 million aggregate principal amount of the notes to cover over-allotments.
The notes&#8217; sale to the initial purchasers will likely settle on June 17, 2025, subject to customary closing conditions, resulting in $1.72 billion in net proceeds.
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44671105/cloudflare-acquires-outerbase-to-streamline-ai-app-development-our-goal-is-to-make-it-easy-and-accessible-for-any-developer" target="_blank" rel="noreferrer noopener">Cloudflare Acquires Outerbase To Streamline AI App Development, &#8216;Our Goal Is To Make It Easy And Accessible For Any Developer&#8217;</a>
Cloudflare may redeem the notes for cash if the last reported sale price of the stock has been at least 130% of the conversion price, which is then in effect for at least 20 trading days during any 30 consecutive trading day period.
The notes will be convertible at a premium of approximately 45% to the last reported sale price of $170.81 per share on June 12, 2025.
In connection with the pricing of the notes, Cloudflare entered into privately negotiated capped call transactions with certain of the initial purchasers and/or their respective affiliates and/or other financial institutions.
The cap price of the capped call transactions is approximately $469.73 per share, representing a premium of approximately 175% over the last reported sale price of $170.81.
Cloudflare intends to use approximately $248.0 million of the net proceeds to pay the cost of the capped call transactions. The remainder of the net proceeds from the offering will be used for general corporate purposes, which may include working capital, capital expenditures, repayment of outstanding indebtedness, and potential acquisitions and strategic transactions.
Cloudflare held $1.91 billion in cash and equivalents <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45303427/cloudflare-stock-rises-on-q1-earnings-after-landing-largest-contract-in-company-history-innovation-wins-in-a-constantly-changing-world" rel="noreferrer noopener">as of March 31, 2025</a>.
The company reported first-quarter revenue of&nbsp;$479.09 million, up 27% compared to&nbsp;estimates&nbsp;of $469.28 million. It reported adjusted EPS of&nbsp;16 cents compared to estimates of 17 cents.
Cloudflare expects second-quarter revenue of $500 million-$501 million versus estimates of $500.34 million. The company anticipates second-quarter adjusted earnings of 18 cents versus estimates of 19 cents.
Price Action: NET stock is trading lower by 2.78% to $166.06 premarket at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/45912952/oracles-ai-ambitions-take-flight-after-record-cloud-growth-what-do-analysts-really-think">Oracle&#8217;s AI Ambitions Take Flight After Record Cloud Growth: What Do Analysts Really Think?</a></li>
</ul>
Photo via Shutterstock

Offerings

Movers

Cloudflare Raises $1.75 Billion In Note Offering, Eyes Growth and Strategic Moves

Wells Fargo analyst Michael Turrin downgrades Dayforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) from Equal-Weight to Underweight and lowers the price target from $60 to $50.

Wells Fargo Downgrades Dayforce to Underweight, Lowers Price Target to $50

HC Wainwright &amp; Co. analyst Scott Buck reiterates Rezolve AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) with a Buy and maintains $4 price target.

RZLV

HC Wainwright & Co. Reiterates Buy on Rezolve AI, Maintains $4 Price Target

Wells Fargo analyst Andrew Nowinski upgrades Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) from Equal-Weight to Overweight and raises the price target from $260 to $385.

Wells Fargo Upgrades Zscaler to Overweight, Raises Price Target to $385

WIIM

NCLH

Shares of cruise stocks are trading lower following Israel's strikes on Iran, which have raised fuel prices and could cloud travel demand outlook.

UBS analyst Avinatan Jaroslawicz initiates coverage on EMCOR Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>) with a Buy rating and announces Price Target of $570.

Initiation

UBS Initiates Coverage On EMCOR Group with Buy Rating, Announces Price Target of $570

President Donald Trump&#8216;s administration will extend existing 50% steel tariffs to imported home appliances, including refrigerators, dishwashers, washing machines, and cooking ranges, beginning June 23.
What Happened: The Commerce Department announced Thursday that the expanded tariffs will cover eight major appliance categories: combined refrigerator-freezers, small and large dryers, washing machines, dishwashers, chest and upright freezers, cooking stoves and ranges, food waste disposals, and welded wire racks, reported Reuters.
According to the Federal Register posting, tariffs will be &#8220;assessed on these derivative products for the value of the steel content in each product.&#8221;
This marks the second expansion of Trump&#8217;s steel tariff program since March, when the administration initially raised import duties from 25% to 50% on steel and aluminum. The first expansion in March added nearly 300 product categories ranging from horseshoes to bulldozer blades.
Trump <a href="https://www.benzinga.com/news/topics/25/05/45708977/trump-doubles-steel-tariffs-to-50-saying-it-will-secure-american-jobs-backs-us-steels-takeover-by-japans-nippon">doubled steel tariffs</a> to 50% on May 31, calling it a &#8220;major announcement&#8221; to protect American jobs. Speaking at a U.S. Steel facility in Pennsylvania, Trump said he initially considered 40% but raised it after industry feedback. &#8220;At 25% they can sorta get over that fence,&#8221; Trump stated. &#8220;At 50% nobody&#8217;s getting over that fence.&#8221;
See Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45921146/shopify-teams-up-with-coinbase-stripe-to-roll-out-usdc-stablecoin-payments-for-merchants">Shopify Teams Up With Coinbase, Stripe To Roll Out USDC Stablecoin Payments For Merchants</a>
Why It Matters: The appliance expansion creates new cost pressures for manufacturers and consumers already facing elevated steel prices. Industry analysts warn the tariffs could add substantial costs to production.
Bloomberg&#8217;s Matthew Miller noted that steel represents approximately 2,800 pounds per vehicle, translating to &#8220;almost <a href="https://www.benzinga.com/markets/tech/25/06/45786145/trumps-50-steel-tariff-could-drive-up-the-costs-for-automakers-almost-2000-of-cost-for-each-car">$2,000 of cost for each car&#8221;</a> as hot-rolled steel approaches $1,000 per ton.
Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) <a href="https://www.benzinga.com/markets/equities/25/06/45841311/trumps-steel-tariffs-hits-straight-on-fords-core-analyst-sees-higher-input-costs-and-eroding-pricing-power-for-tesla-rival">faces particular exposure</a> due to its U.S.-centric manufacturing model. Alex Tsepaev, chief strategy officer at B2PRIME Group, told Benzinga that &#8220;A 50% tariff could inflate COGS significantly just as pricing power erodes in both EV and ICE segments.&#8221; Ford suspended financial guidance in Q1 amid tariff uncertainty following a 65% profit decline.
<div class="wp-block-group is-layout-constrained wp-block-group-is-layout-constrained">
The 2018 Trump-era steel tariffs provide historical context. While U.S. steel production rose slightly, a 2023 International Trade Commission report found the tariffs reduced output in vehicle, machinery, and tool sectors by over $3 billion by 2021, suggesting a net negative economic impact. The U.S. imported $31.3 billion in iron and steel last year, with Canada supplying $7.6 billion worth of materials. The expanded tariffs take effect as domestic steel prices have already climbed due to reduced foreign competition since March. Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45921026/chinese-antitrust-regulator-delays-35-billion-us-chip-merger-amid-trade-tensions-report">Chinese Antitrust Regulator Delays $35 Billion US Chip Merger Amid Trade Tensions: Report</a> </li>
</ul>
</div>
Photo courtesy: Joey Sussman / Shutterstock.com

Politics

Trump Extends 50% Steel Tariffs To Home Appliances Like Fridges, Dishwashers Starting June 23

CRTO

Criteo Expands Global Partnership With Dentsu To Power Full-Stack Commerce Media Campaigns

BCRX

BioCryst Pharmaceuticals Announced That National Institute Of Drug And Food Surveillance In Colombia Has Granted Approval For Oral, Once-daily ORLADEYO (berotralstat) For Prophylaxis Of Hereditary Angioedema Attacks In Adults And Pediatric Patients 12 Years Or Older

Citigroup analyst Patrick Cunningham downgrades Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) from Buy to Neutral and lowers the price target from $405 to $385.

Citigroup Downgrades Sherwin-Williams to Neutral, Lowers Price Target to $385

BEAM

Beam Therapeutics Announces New Data From BEACON Phase 1/2 Clinical Trial Of BEAM-101 Supporting Differentiated Profile In Sickle Cell Disease At European Hematology Association 2025 Congress; Company Says Enrollment Complete In Both Adult And Adolescent Cohorts Of BEACON Trial, With 30 Patients Expected To Be Dosed By Mid-2025

Fractyl Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will present a poster of new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform at the American Diabetes Association's (ADA) 85th Scientific Sessions being held June 20-23, 2025, in Chicago, Illinois.
Poster Presentation Details
Session Title: Late Breaking Poster Session Abstract Title: Single-Dose GLP-1–Based Pancreatic Gene Therapy Prevents Obesity and Diabetes in High-Fat–Fed Mice Poster Number: 1970-LB Date and Time: Sunday, June 22, 2025, 12:30 p.m. – 1:30 p.m. Location: Poster Hall (Hall F1, Level 3)

GUTS

Fractyl Health To Present Poster Of New Preclinical Data From Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform At ADA 85th Scientific Sessions

MoneyHero (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNY#NASDAQ">MNY</a>) reported quarterly losses of $(0.10) per share. This is a 66.67 percent increase over losses of $(0.30) per share from the same period last year. The company reported $14.31 million in sales this quarter. This is a 35.45 percent decrease over sales of $22.18 million the same period last year.

Earnings

MoneyHero Q1 EPS $(0.10) Up From $(0.30) YoY, Sales $14.31M Down From $22.18M YoY

JP Morgan analyst Andrea Teixeira upgrades Newell Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) from Neutral to Overweight and raises the price target from $6 to $7.

JP Morgan Upgrades Newell Brands to Overweight, Raises Price Target to $7

– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma –
– In combination with small molecule inhibitors, ARV-393 demonstrated enhanced tumor growth inhibition, including tumor regressions, in models of aggressive diffuse large B-cell lymphoma (DLBCL) –
NEW HAVEN, Conn., June 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical studies of ARV-393, the company's investigational PROteolysis TArgeting Chimera (PROTAC) B-cell lymphoma 6 protein (BCL6) degrader. BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. ARV-393 demonstrated significant single-agent activity in a patient derived xenograft (PDX) model of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (nTFHL-AI also known as AITL) and PDX models of transformed follicular lymphoma (tFL). In combination with oral small molecule inhibitors (SMIs), ARV-393 demonstrated enhanced antitumor activity, including tumor regressions, in cell line-derived xenograft (CDX) models of high-grade B-cell lymphoma (HGBCL) and aggressive diffuse large B-cell lymphoma (DLBCL). The results from these preclinical studies were shared at the European Hematology Association (EHA) 2025 Congress in Milan, Italy.
Key findings from the preclinical studies included:
<ul>
<li>Single-agent ARV-393 significantly reduced tumor burden in peripheral blood, bone marrow and spleen in a systemic PDX model of nTFHL-AI derived from a patient who relapsed post chemotherapy. This is potentially the first preclinical evidence of anti-tumor activity with an efficacious BCL6-targeted small-molecule degrader in a human nTFHL-AI model.</li>
<li>ARV-393 monotherapy treatment resulted in robust (≥95%) tumor growth inhibition (TGI) in two PDX models of tFL.</li>
<li>ARV-393 in combination with 5 classes of SMIs targeting potentially cooperative oncogenic drivers (tazemetostat, palbociclib, everolimus, acalabrutinib, or venetoclax) demonstrated increased TGI in CDX models of HGBCL and aggressive DLBCL compared with the respective monotherapy treatments. Tumor regressions were observed when ARV-393 was combined with tazemetostat, palbociclib, acalabrutinib, or venetoclax.</li>
<li>RNA sequencing studies carried out to further characterize downstream mechanism of action suggested that ARV-393 inhibits tumor cell cycle progression and promotes differentiation, driving antitumor activity and broad combinability in preclinical models.</li>
</ul>

ARVN

Arvinas Presents Data From Preclinical Studies Of ARV-393, PROTAC B-Cell Lymphoma 6 Protein Degrader, At EHA 2025 Congress

Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>, HKEX: 9688))) today announced new data from its preclinical study of ZL-1503, the Company's promising IL-13/IL-31R bispecific antibody, demonstrating its ability to simultaneously suppress the inflammatory and pruritogenic (itch-causing) pathways in atopic dermatitis (AD). The findings, featured during a poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, Scotland, highlight the potential of ZL-1503 as a novel treatment option for moderate-to-severe AD.
Medications that inhibit IL-4/IL-13 signaling have markedly improved the therapeutic landscape for AD. Certain AD symptoms are mediated by IL-31; however, they are only partially alleviated by IL-4/IL-13 inhibition. As a result, many patients experience slow and modest clinical responses to currently available medications.
ZL-1503 was evaluated in a pilot preclinical study in non-human primates to assess its long-term effects on IL-31-mediated scratching and IL-13-induced signaling (pSTAT6). Key study results presented at the EAACI Congress 2025 include:
<ul>
<li>An intravenous single dose of ZL-1503 (10 mg/kg, iv) completely inhibited IL-13-mediated pSTAT6 and IL-31-induced scratching for at least 76 days in all preclinical subjects.</li>
<li>Two out of three subjects exhibited prolonged IL-13-mediated pSTAT6 inhibition for over 118 days, and one out of three subjects sustained IL-31-induced scratching inhibition for over 133 days.</li>
<li>Pharmacokinetic (PK) analysis of serum samples collected during the study revealed that ZL-1503 exhibited slow clearance, correlating closely pharmacodynamic (PD) responses, demonstrating strong PK/PD relationships in blocking IL-13 and IL-31 pathways in the preclinical model.</li>
<li>ZL-1503 was well tolerated following weekly IV dosing up to 150 mg/kg.</li>
<li>Additionally, in vitro studies showed that binding to one target did not affect ZL-1503's blocking effects on the other target.</li>
</ul>

ZLAB

Zai Lab Unveils New Atopic Dermatitis Drug That Blocks Both Itch and Inflammation for Over 3 Months in Study

Press Releases

Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill

Protagonist Therapeutics Reports Granting of Inducement Award

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update

Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

Comments

Protagonist Therapeutics

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL